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Abstract
Suspicion of sepsis in neutropenic patients requires immediate antimicrobial treatment. The initial regimen in
critically ill patients should cover both Gram-positive and Gram-negative pathogens, including Pseudomonas
aeruginosa. However, the risk of selecting multidrug-resistant pathogens should be considered when using broad-
spectrum antibiotics for a prolonged period of time. The choice of the first-line empirical drugs should take into
account the underlying malignancy, local bacterial ecology, clinical presentation and severity of acute illness. This
review provides an up-to-date guide that will assist physicians in choosing the best strategy regarding the use of
antibiotics in neutropenic patients, with a special focus on critically ill patients, based on the above-mentioned
considerations and on the most recent international guidelines and literature.
Introduction
Neutropenia is defined as a neutrophil count ≤ 500/
mm
3 or ≤ 1000/mm
3 with a predicted decrease to ≤
500/mm
3 [1,2]. Infection remains a major complication
of neutropenia, and severe sepsis and septic shock are
associated with high hospital mortality [3,4]. Fever,
defined as a single oral temperature ≥38.3°C or ≥38.0°C
for at least 1 hour, develops in 10-50% of patients after
chemotherapy for solid tumors and in more than 80% of
patients with hematological malignancies [5].
Urgent and appropriate antibiotic administration is
mandatory to prevent further clinical deterioration, espe-
cially in critically ill patients with signs of respiratory dis-
tress or severe sepsis. Therefore, the first-line antibiotics
should cover the pathogens deemed to be most likely
based on the patient’s characteristics, neutropenia, and
local epidemiology. However, the changing epidemiology
of infections, global increase in resistant strains, and need
to contain healthcare costs require careful selection of
antibiotics. Only 10-40% of episodes of febrile neutrope-
nia are microbiologically documented in neutropenic
patients, which hampers appropriate antibiotic spectrum
adjustment in most cases [5]. This review provides an
up-to-date guide to assist physicians in choosing the opti-
mal antibiotic regimen in neutropenic patients, based on
the above-mentioned considerations and on the most
recent international guidelines and literature.
Bacterial epidemiology in neutropenic patients
During the 1990s, Gram-positive bacteria emerged as the
leading agents responsible for infections in neutropenic
patients worldwide. In adults with bloodstream infections
and malignancies in the United States, the proportion of
Gram-positive organisms increased from 62% in 1995 to
76% in 2000, whereas the proportion of Gram-negative
infections decreased from 22% to 15% [6]. Factors that
may increase the risk of Gram-positive sepsis in neutro-
penic patients include the widespread use of central
venous catheters, introduction of prophylactic quinolone
therapy, increased use of proton pump inhibitors, and
rising prevalence of chemotherapy-induced mucositis [7].
Importantly, Gram-negative bacteria seem to be causing
an increasing number of infections in neutropenic
patients since the early 2000s (Table 1). The selection of
empirical antimicrobials depends in part on an assess-
m e n to fw h i c hp a t h o g e n sa r em o s tl i k e l yt ob ei n v o l v e d .
Table 2 shows a nonexhaustive list of pathogens with
their possible sites of development in neutropenic
patients. Although Gram-negative bacteria are usually
associated with severe infections that have high mortality
rates, coagulase-negative staphylococci (CNS), which are
recognized as the most common causes of nosocomial
bacteremia, often are associated with more indolent
forms of infections and have been more prevalent among
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any medium, provided the original work is properly cited.Table 1 Bloodstream bacterial isolates in clinical trials enrolling neutropenic adults between 1998 and 2009
Carratala et
al. Arch
Intern Med
1998 [46]
Gruson et
al. Eur
Respir J
1999 [47]
Feld et al.
J Clin
Oncol
2000 [26]
Regazzoni et
al. Intensive
Care Med
2003 [48]
Harter et al.
Bone Marrow
Transplant
2006 [25]
Klastersky et
al. Int J
Antimicrob
Agents 2007
[49]
Metallidis et
al. Eur J
Intern Med
2008 [50]
De La Rubia et al.
Biol Blood
Marrow
Transplant 2009
[51]
No. of patients 39 38 411 62 161 2142 75 428
No. of organisms 43 5 93 16 96 556 13 125
Gram-positive
organisms
18 (41.9) 4 (80) 41 (44.1) 7 (43.7) 70 (72.9) 353 (63.5) 6 (46.1) 81 (64.8)
Staphylococcus
spp
3 (7) 3 (60) 13 (14) 2 (12.5) 52 (54.5) 187 (33.6) 6 (46.1) 56 (44.8)
Streptococcus spp 15 (34.9) 1 (20) 27 (29) 4 (25) 15 (15.6) 114 (20.5) - 10 (8)
Other - - 1 (1.1) 1 (6.2) 3 (3.1) 52 (9.4) - 15 (12)
Gram-negative
organisms
25 (58.1) 1 (20) 52 (55.9) 9 (56.3) 26 (27.1) 203 (36.5) 7 (53.9) 44 (35.2)
Enterobacteriaceae 6 (14) - 42 (45.2) 6 (37.5) 22 (23) 123 (22.1) 4 (76.9) -
P. aeruginosa 17 (39.5) 1 (20) 6 (6.5) 2 (12.5) 3 (3.1) 49 (8.8) 2 (15.3) -
Other 2 (4.6) - 4 (4.3) 1 (6.3) 1 (1) 31 (5.6) 1 (7.7) -
Table 2 Nonexhaustive list of bacteria that cause disease in febrile neutropenic patients, with their usual sites of
development
Site of infection
Gram-positive bacteria
Coagulase-negative staphylococci Bloodstream infections, catheter-associated sepsis
Viridans group streptococci Bloodstream infections, endocarditis
Enterococcus faecium
Enterococcus faecalis
Bloodstream infections, endocarditis
Stomatococcus mucilaginosus Bloodstream infections, catheter-associated sepsis
Pediococcus species Urine and bloodstream infections
Corynebacterium jeikeium Endocarditis, catheter-related bacteremia, cutaneous lesions,
and nodular pulmonary infiltrates
Lactobacillus species Bloodstream infections endocarditis, meningitis, intraabdominal
abscesses, and pneumonia
Rhodococcus equi Suppurative pneumonia
with pulmonary abscesses and empyema
Clostridium septicum Metastatic myonecrosis, typhlitis
Gram-negative bacteria
P. aeruginosa Pneumonia, bloodstream infections
Escherichia coli,
Klebsiella species,
Enterobacter
Bloodstream infections, catheter-associated sepsis, and pneumonia
Stenotrophomonas maltophilia Pneumonia, bloodstream infections
Alcaligenes xylosoxidans and
Burkholderia cepacia
Catheter-associated sepsis
Capnocytophaga species Bloodstream infections in bone marrow transplant recipients
Anaerobes
Fusobacterium nucleatum Bloodstream infections,
ulcerative pharyngitis, and nodular pulmonary infiltrates due to septic emboli
Leptotrichia buccalis Bloodstream infections with
extensive mucosal involvement in severely immunosuppressed patients
Mycobacteria Mycobacterium chelonae
Mycobacterium fortuitum
Pneumonia, disseminated infections
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the setting of sustained bacteremia, CNS is an emerging
cause of nosocomial endocarditis, usually occurring as a
complication of catheter-related infection [9]. Viridans
group streptococcal bacteremia may be associated with
fulminant infection and is common in patients with hema-
tological malignancies and profound neutropenia [6].
A major concern is the emergence of multidrug-resis-
tant bacteria [10,11]. Among Gram-negative rods, Pseu-
domonas aeruginosa, Escherichia coli, Citrobacter
freundii, Acinetobacter species, and Stenotrophomonas
maltophilia are increasingly found to exhibit multidrug-
resistance (i.e., resistance to three or more classes of
antimicrobials), extensive drug resistance (i.e., resistance
to all but one or two classes), or pandrug-resistance (i.e.,
resistance to all available classes) [12]. Antibiotic selec-
tion pressure promotes the induction of extended-spec-
trum chromosomal b-lactamases (ESBL) after the use of
b-lactams [13,14] and the selection of enterobacteria
with decreased porin production after the use of carba-
penems [11]. ESBL-producing Enterobacteriaceae are
now commonly isolated in the community [15]. Further-
more, Enterobacteriaceae that produce Klebsiella pneu-
moniae carbapenemases (KPCs) are now reported
worldwide, and KPCs have become the leading class A
carbapenemases. KPC b-lactamases confer decreased
susceptibility or resistance to virtually all b-lactams [16].
Similarly, fluoroquinolone exposure is associated with
the emergence of methicillin-resistant Staphylococcus
aureus (MRSA) and penicillin-resistant streptococci
[17]. Widespread use of vancomycin has been described
to cause outbreaks of bacteremia due to nosocomial
vancomycin-resistant enterococci associated with high
mortality rates [6]. Finally, other Gram-positive organ-
isms with limited susceptibility or resistance to b-lac-
tams have been increasingly isolated in cancer patients
with febrile neutropenia; examples include Corynebac-
terium jeikeum, Lactobacillus, Bacillus species, and Rho-
dococcus species [12]. Antibiotic resistance rates vary
widely across countries. For instance, the proportion of
P. aeruginosa strains that exhibit carbapenem resistance
is below 10% in Denmark, The Netherlands, Switzer-
land, Sweden, and Finland, greater than 25% in Croatia,
Turkey, Germany, Italy, the Czech Republic, and as high
as 45% in Greece [18].
Principles underlying first-line antibiotic therapy
Antibiotic therapy must be initiated immediately in feb-
rile patients with neutropenia, especially when criteria of
severe sepsis are met [1,2]. The antibiotics used for
first-line therapy must be active against the most likely
pathogens, as estimated based on the suspected source
of infection, patient’s medical history, careful clinical
examination, bacteriological findings, and x-ray results.
Signs and symptoms of inflammation are frequently
minimal or absent in patients with neutropenia. The
initial assessment of patients with febrile neutropenia
should include a careful physical examination for subtle
signs and symptoms of infection, with special attention
to the sinuses and oropharynx, skin and skin folds,
intravenous lines, genital organs, and anal area. Obtain-
ing bacterial samples is crucial to ensure the detection
and susceptibility testing of the causative pathogen.
Most pathogens are isolated from blood cultures, which
must be drawn both from the catheter and from a per-
ipheral vein. Cultures of stool, urine, cerebrospinal fluid,
and/or skin lesions should be performed as indicated by
the clinical picture. Previous microbiological results
should be considered, because carriage of multiresistant
strains may last several weeks or months [19]. A chest
radiograph should be obtained, and high-resolution
computed tomography of the chest may be indicated if
the patient has pulmonary symptoms with an uninfor-
mative chest radiograph or if an invasive mold infection
is suspected [1,2].
Choice of the first-line antibiotic regimen
Route of empirical antibiotic therapy
Although oral antibiotic administration can be an option
in neutropenic patients with the lowest risk of complica-
tions, all patients with prolonged (> 7 days duration)
and/or profound neutropenia (< 100 cells/mm
3)a n d / o r
abdominal pain, nausea and/or vomiting diarrhea and/or
criteria of severe sepsis or septic shock with signs of
organ failure should be treated intravenously. Suspicion
of catheter-related infection or new pulmonary infil-
trates are other indications of intravenous antibiotics
administration.
Antibiotic combinations
The advantages of combination therapy include coverage
of a broad spectrum of pathogens and, theoretically,
synergistic activity with a decrease in the emergence of
resistant strains. The main downsides are ototoxicity
and nephrotoxicity, most notably with aminoglycosides,
and increased cost. It should be pointed out that
nephrotoxicity may occur even with very short courses
of aminoglycosides, particularly with multiple-dose regi-
mens and in patients receiving or having received other
toxic substances (e.g., cisplatin, ciclosporin, amphoteri-
cin B, colistin, acyclovir, or contrast media) [20,21].
So far, no randomized study or metaanalysis has pro-
ven that adding an aminoglycoside or quinolone to a b-
lactam is superior over using a broad-spectrum b-lactam
alone. Results from a recent multicentric propensity
matched cohort study have suggested that early combi-
nation antibiotic therapy is associated with decreased
mortality in septic shock. Although not being the focus
of this study, it is likely that neutropenic patients also
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apy [22]. Given that P. aeruginosa infection is rather
common and associated with high mortality rates in
neutropenic patients [23], the empirical antibiotic regi-
men should cover this pathogen. Monotherapy with cef-
tazidime, imipenem, or piperacillin/tazobactam seems to
be as effective as b-lactam/aminoglycoside combinations,
even in the subset of bacteremic patients [1,2].
There are no studies of b-lactam/aminoglycoside com-
binations in critically ill neutropenic patients. According
to the aforementioned guidelines, b-lactam plus amino-
glycoside combinations may be justified in patients with
severe sepsis or septic shock and in those with sus-
pected resistant Gram-negative infections. The safety of
cefepime has recently been put into question by a meta-
analysis, suggesting an increase risk of death associated
with the use of cefepime in neutropenic patients [24].
The mechanism underlying such an association could
not been identified. However, the U.S. Food and Drug
Administration (FDA) still approves cefepime based on
a new metaanalysis performed by the Agency, including
additional data, which did not find any increase in mor-
tality in cefepime-treated compared with control
patients [2].
Ciprofloxacin has good activity against Gram-negative
bacteria, including Pseudomonas aeruginosa, but poor
coverage of Gram-positive organisms. Levofloxacin has
better activity against Gram-positive organisms but less
activity against Pseudomonas aeruginosa. However,
fluoroquinolones use is associated with the emergence
of antibiotic-resistant pathogens, and therefore, their use
in initial empirical regimens should be discouraged, par-
ticularly in patients with a history of quinolone-based
prophylaxis.
In febrile neutropenic patients, efficacy seems largely
equivalent with b-lactam monotherapy by cefepime,
piperacillin/tazobactam, and carbapenems [1,2,25,26]
(Table 3). Ceftazidime monotherapy may be an effective
strategy. However, the limited activity of ceftazidime
against Gram-positive bacteria is of concern in high-risk
neutropenic patients, because streptococcal bacteremia
is associated with high complication rates [27]. Although
most broad spectrum b-lactams (cefepime, piperacillin/
tazobactam, and carbapenems) provide coverage against
most Gram-positive bacteria, some Gram-positive
organisms, such as S. mitis, methicillin-resistant S. aur-
eus, Enterococcus faecium, and Corynebacterium species,
may be resistant to b-lactams and susceptible only to
glycopeptides (i.e., vancomycin and teicoplanin), quinu-
pristin-dalfopristin, daptomycin, or linezolid. The appro-
priateness of adding vancomycin to a b-lactam has long
been a matter of debate. Given the risk of emergence of
resistant pathogens due to widespread vancomycin use
and the often relatively indolent course of infections due
to the most commonly isolated resistant Gram-positive
organisms (i.e., CNS), routinely adding vancomycin to
the first-line regimen is now strongly discouraged in
stable patients [1,2,28]. In contrast, the vancomycin/b-
lactam combination remains recommended for the first-
line treatment of patients with severe sepsis or septic
shock and of patients at high risk for infection by anti-
biotic-resistant Gram-positive cocci (i.e., those with pro-
longed (> 7 days) and profound (absolute neutrophil
count < 100 cells/mm
3) neutropenia and/or presenting
with hypotension, pneumonia, new-onset abdominal
pain, or neurologic changes [1,2], Table 3).
In a randomized, controlled study of neutropenic
patients with cancer, linezolid and vancomycin produced
similar outcomes [29]. The limited data on linezolid and
the bacteriostatic activity of this drug are of concern
when treating neutropenic patients. Linezolid may
finally cause marrow suppression when given for more
than 14 days. Limited data exist on daptomycin in neu-
tropenic patients, but it may represent an alternative in
selected situations [30].
In all likelihood, no guidelines of universal relevance
can be developed. Instead, the global epidemiology of
bacterial infections should be considered in conjunction
with local rates of pathogen isolation and resistance.
The patient’s own ecology also should be considered.
Valuable information can be garnered from a review of
previous anterior nasal and rectal swabs, which may
have shown colonization by antibiotic-resistant bacteria
(e.g., methicillin-resistant S. aureus, P. aeruginosa, multi-
drug-resistant Gram-negative bacilli, and vancomycin-
resistant enterococci). A history of infection should raise
the possibility of a recurrence and should prompt the
use of antibiotics active against the pathogen involved.
Finally, renal and hepatic function and the risk of aller-
gies may influence the choice of the first-line antibiotics.
Adapting the antibiotics: treatment duration
Failure to respond to empirical therapy is defined as
persistent fever and the development of serious medical
complications. The median time to defervescence in
hospitalized patients with cancer is 5-7 days, although
low-risk patients often respond within 2 days or less
[1,2]. International guidelines recommend a reassess-
ment of the initial antibiotic regimen after 3-5 days if
the fever persists [1,2]. Persistence of fever with clinical
deterioration or infectious disease progression should be
distinguished from persistence of fever in a clinically
stable patient. Patients whose clinical status deteriorates
r e q u i r eac o m p l e t er e a s s e s s m e n t ,i n c l u d i n gac a r e f u l
physical examination and the collection of new culture
specimens to look for a second infection. Ultrasonogra-
phy and high-resolution computed tomography should
be performed as indicated by the clinical data, and the
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related infection is proven or strongly suspected. If a
resistant pathogen is isolated or suspected to be respon-
sible for the deterioration (i.e., if present in a recent
stool culture) and is not covered by initial empirical
regimen, the treatment should be modified promptly.
Empirical addition of a glycopeptide, if not used initially,
may be warranted, and switching from piperacillin-tazo-
bactam or a third-generation cephalosporin to a carba-
penem as second-line therapy should be considered
(Figure 1). Finally, empirical addition of antifungal
agents deserves consideration in patients who have risk
factors for fungal infection [1,2,28,31]. The management
of antifungal therapy is beyond the scope of this chapter,
but readers can refer to specific reviews on this topic
[31-33]. For clinically stable patients with persistent fever,
there is no published evidence to support a change in the
antibiotic regimen. Moreover, the widespread emergence
of multiresistant and panresistant bacterial strains should
discourage “escalating” strategies, such as switching from
piperacillin-tazobactam or cefepime to a carbapenem or
adding vancomycin. When a causative pathogen is
identified, the antibiotic regimen should be adapted
based on the antibiotic susceptibility test results. The
dwindling number of drugs in the pharmaceutical pipe-
line and the increased incidence of multidrug-resistant
bacteria have led to the increasing use of old antibio-
tics, such as colistin [34].
Colistin exhibits rapid and concentration-dependent
bactericidal activity with relatively low rates of resis-
tance. Good rates of clinical responses have been
reported in patients infected with multidrug-resistant
Table 3 Suggested dosages for empirical antibiotic therapy in high-risk adult neutropenic patients with normal renal
function
Dosage Targets for serum concentrations
Cefepime 2 g iv every 8-12 hours Max. T > MIC (at least 70% of the
dosing interval)
Piperacillin-
tazobactam
#
4 g/500 mg iv every 6-8 hours Max. T > MIC (at least 70% of the
dosing interval)
Ceftazidime
# 1-2 g every 8 hours or
2 g loading dose followed by 6 g continuous iv
infusion every 24 hours
Max. T > MIC (at least 70% of the
dosing interval)
Imipenem
# 500 mg every 6 hours to 1 g iv every 6-8 hours
Up to 50 mg/kg/day
for seriously ill patients: 1 g iv every 6-8 hours
Max. T > MIC (at least 70% of the
dosing interval)
Meropenem
# 0.5-1 g iv infusion every 8 hours
for seriously ill patients: 1 g iv infusion every 8 hours
Max. T > MIC (at least 70% of the
dosing interval)
Amikacin* 15-20 mg/kg once daily
for seriously ill patients: 25-30 mg/kg once daily
Peak/MIC ratio > 8-10 Peak: 64-80 μg/ml
Trough < 2.5 μg/ml
Gentamicin*
tobramycin*
3-5 mg/kg iv once daily
for seriously ill patients: 7-8 mg/kg iv once daily
Peak/MIC ratio > 8-10 Peak: 32-40 μg/ml
Trough < 0.5 μg/ml
Vancomycin* 15-20 mg/kg ¤ given every 8-12 hours
for seriously ill patients: loading dose of 25-30 mg/kg
or
loading dose of 15 mg/kg iv followed by 30-60 mg/kg
continuous iv infusion every 24 hours
Optimal 24 h-AUC/MIC ratio > 400 Trough: > 15-20 mg/L,
25-35 mg/L if severe infection
Always > 10 mg/L to avoid the
development of resistance
Teicoplanin* 6-12 mg/kg every 12 hours iv from day 1 to 4 followed
by 6-12 mg/kg every 24 hours
Optimal 24 h-AUC/MIC ratio > 400 Trough: 20-30 mg/L
Ciprofloxacin
# 400 mg every 8-12 hours Optimal 24 h-AUC/MIC ratio ~125
for Gram-negative bacteria
Optimal 24 h-AUC/MIC ratio ~40
for Gram-positive bacteria
Colimycin 75,000-150,000 IU/kg (2.5-5 mg/kg colistin base) every
24 hours in 3 divided doses
The local bacterial ecology and patient’s bacterial history must be considered when selecting empirical antibiotics.
#Note that the highest suggested dosage is active against Pseudomonas aeruginosa.
*Routine determination of trough serum levels is required. For aminoglycosides, renal impairment may occur after a few days of treatment; therefore, treatment
duration should be limited to 48-72 hours and should not exceed 5 days. Multiple daily doses of aminoglycosides are discouraged, because this regimen does
not reduce toxicity and cannot provide sufficient peak serum concentrations; peak concentration should be determined 30 minutes after the end of the infusion
and trough concentration just before the next infusion. For vancomycin, trough serum concentrations should be obtained just before the fourth dose. There is
no evidence that continuous infusion regimens improve patient outcomes. The recommended infusion rate is 0.5-1 g/h. Monitoring of trough serum vancomycin
concentrations is recommended for patients receiving aggressive dose targeting, for patients with unstable renal function, and for patients receiving concurrent
treatment with nephrotoxic agents.
¤Should be calculated based on actual body weight.
iv, intravenous.
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therapy. Colistin may act synergistically with rifampin or
carbapenems against metallo-b-lactamase-producing
(MBL) K. pneumoniae or A. baumannii strains. How-
ever, these data on colistin are chiefly from nonrando-
mized studies in small numbers of patients. Although
the manufacturer recommends not exceeding 6 million
units per day, a growing number of clinicians now routi-
nely use daily dosages of up to 9 million IU in two to
four divided doses (12,500 IU of colistin is equivalent to
1 mg of the prodrug colistin methanesulfonate). Inhala-
tional colistin therapy has long been used in patients
with cystic fibrosis and is now proposed in critically ill
patients with ventilator-associated pneumonia. However,
clinical data are derived from small, retrospective, non-
randomized studies. We have very little information on
colistin pharmacokinetics and pharmacodynamics, espe-
cially in critically ill patients. Recently, Lu et al. reported
that inhaled colistin resulted in relative higher lung tis-
sue bioavailability in piglets compared with animals trea-
ted with intravenous colistin [35]. Nephrotoxicity
associated with the use of colistin remains a matter of
concern. In vitro studies have shown that the toxic
effects of colistin on mammalian cells are concentra-
tion-dependent and time-dependent. Colistin nephro-
toxicity seems rare in young patients with normal renal
function and common in patients with underlying renal
insufficiency. The risk may depend on the cumulative
dose. Colistin nephrotoxicity is usually mild and almost
always reversible within a few weeks or months after
treatment discontinuation.
When no antibiotic-resistant Gram-positive bacteria
are isolated, withdrawal of glycopeptides is warranted
and may limit the emergence of vancomycin-resistant
enterococci and the risk of nephrotoxicity [1,2,11]. Simi-
larly, de-escalation (e.g., switching from carbapenem to
cefepime or piperacillin-tazobactam) should be encour-
aged when no microorganism resistant to the first-line
regimen is isolated.
In patients with sustained bacteremia and/or persis-
tent fever and clinical deterioration, a portal of entry
requiring specific treatment should be sought. Necrotiz-
ing cellulitis or peritonitis requires surgery. One of the
commonest problems is deciding whether to remove the
indwelling central venous catheter in bacteremic
patients. The decision rests on the clinical presentation
(septic shock, local tunnel, or port infection), pathogen,
presence of intestinal colonization, and differential time
to blood culture positivity of samples drawn simulta-
neously by phlebotomy and through the catheter. In
patients with bacteremia due to Enterobacteriaceae,
enterococci or Pseudomonas,w i t hn ol o c a ls i g n so f
catheter infection or septic shock, the conjunction of
intestinal colonization and microbial growth in
Figure 1 Suggested adjustments to the empirical antibiotic regimen in patients with persistent fever after 3-5 days treatment.
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in a sample obtained simultaneously from the catheter
hub often indicates bacterial translocation from the
intestine [36]. Further information regarding the man-
agement of catheter-related infections can been found in
recently published guidelines [37].
Current guidelines recommend continued intravenous
administration of antibiotics after 48 hours of apyrexia,
for at least 2 days after neutropenia resolution or for 4-
5 days if the fever persists [1]. Clinically or microbiolo-
gically documented infection may require longer treat-
ment but with narrower-spectrum antibiotics (i.e., a
neutropenic patient who has bacteremia due to multi-
susceptible E. coli treated with piperacillin-tazobactam
should be switched to amoxicillin for a few additional
days after neutropenia recovery).
International guidelines recommend that patients with
persistent neutropenia remain on antibiotics for at least
2 weeks. All patients with persistent fever, with or with-
out clinical deterioration, should be investigated for
noninfectious causes of fever (Table 4). Finally, antibio-
tic dose adjustment based on serum concentration
determination may be required, because changes in the
pharmacodynamics and pharmacokinetics of antibiotics
have been reported in neutropenic patients [38-40].
Pharmacodynamic and pharmacokinetic considerations
The pharmacokinetics and pharmacodynamics of many
antibiotics are modified in neutropenic [38] and/or criti-
cally ill patients. The volume of distribution and clear-
ance are increased, and therefore the half-life and
plasma concentrations may be lower than in control
patients. Many animal studies found decreases in the
bactericidal activity of b-lactams in neutropenic animals.
Given that the activity of b-lactams and glycopeptides
depends on the time spent with serum drug concentra-
tions greater than the minimum inhibitory concentra-
tion of the organism, decreasing the interval between
doses or using a continuous infusion may be the best
strategy for administering b-lactams and glycopeptides
to neutropenic patients. In any case, therapeutic drug
monitoring is valuable for guiding dosage adjustments
and ensuring that therapeutic concentrations are
achieved to increase the chances of eradicating the
organism and to minimize the risk of selecting antibio-
tic-resistant bacteria [38,41]. Serum vancomycin and tei-
coplanin levels should be monitored routinely [39]. In
neutropenic patients who receive the recommended 2 g/
day dose of imipenem, many may have serum concen-
trations below the therapeutic range [41]. When using
carbapenems in neutropenic patients, 50-60% of the
dosing interval must be spent above the minimum inhi-
bitory concentration to achieve bactericidal activity, and
success rates improve when 75-100% of the dosing
interval is spent above the minimum inhibitory concen-
tration [41-43]. Plasma carbapenem levels can be mea-
sured by using high-performance liquid chromatography
in patients with persistent fever to ensure that the
plasma concentrations are within the therapeutic range.
Aminoglycosides, in contrast, have a concentration-
dependent bactericidal activity. Elimination of aminogly-
cosides is highly dependant on renal clearance, and
accumulation is likely to occur in patients with renal
failure. Once-daily administration of aminoglycosides
often is preferred over multiple-daily dosing to reduce
the risk of nephrotoxicity and is recommended in the
few neutropenic patients who require an aminoglycoside
in combination with a wide-spectrum b-lactam [28].
When using aminoglycosides, therapeutic drug monitor-
ing is important to minimize the risk of renal and
cochlear/vestibular toxicity [40]. A recently published
review is available for readers who wish further informa-
tion on antibiotic pharmacokinetics and pharmacody-
namics in neutropenic patients [38].
Prophylactic antibiotics and hygiene mesures
The guidelines issued by the European Conference on
Infections in Leukaemia recommend prophylactic cipro-
floxacin or levofloxacin therapy from chemotherapy
initiation to neutropenia resolution [28]. According to
Table 4 Causes of fever persistence after initial empirical
antibiotic in neutropenic patients
Infectious causes of persistent fever
Inappropriate antibiotic dosing and concentration
Clostridium difficile-induced diarrhea
Antibiotic-resistant
pathogen
Multidrug-resistant bacteria,
Mycobacteria,
Fastidious pathogens (e.g., Legionella,
Mycoplasma, Chlamydia pneumoniae, Bartonella)
Fungal infection Molds: Aspergillus and zygomycetes
Yeasts: Candida and Cryptococcus
Parasitic infection e.g., Toxoplasma gondii
Viral infection e.g., herpesviruses (cytomegalovirus, Epstein-
Barr virus, human herpesvirus 6, varicella-zoster
virus, herpes simplex virus) parainfluenza virus,
respiratory syncytial virus, influenza viruses.
Persistent focus of infection (e.g., catheter)
Uncontrolled infection (e.g., endocarditis or peritonitis)
Noninfectious causes of persistent fever
Transfusion-related
fever
Hemophagocytic lymphohistiocytosis
Venous thrombosis
Drug- or transfusion-induced fever
Graft-versus-host
disease
Underlying
malignancy
Pancreatitis
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(IDSA) guidelines, such prophylaxis should only be con-
sidered [2]. In fact, many centers still do not give quino-
lone prophylaxis to patients with afebrile neutropenia,
due to concerns about the emergence of antibiotic resis-
t a n c ei nt h el o n gr u n[ 1 7 ] .T h es e l e c t i o no fr e s i s t a n t
o r g a n i s m sb yq u i n o l o n e si sas e r i o u sh a z a r d ,a sr e -
emphasized recently [44]. The emergence of resistant
strains should be monitored in centers where quino-
lone-based prophylaxis is used [2,10,45]. Hand hygiene
remains the most effective measure to prevent hospital-
acquired infections, whereas isolation into a single-
patient room or use of specific protective gear (gowns,
gloves, and masks) are not mandatory except for hema-
topoietic stem cell transplant recipients.
Conclusions
Antibiotic therapy must be initiated promptly in febrile
neutropenic patients. In high-risk patients, initial
empirical treatment with piperacillin-tazobatam or cefe-
pime is recommended. In addition, the initial antibiotic
strategy should be adapted based on the basis of initial
clinical assessment, bacterial ecology in the hospital,
and bacterial history in the patient. The use of vanco-
mycin should be reserved for patients with suspected
methicillin-resistant Gram-positive infections and/or
signs of severe sepsis or septic shock. There is some
evidence to support adding an aminoglycoside to the
extended-spectrum b-lactams in critically ill neutropenic
patients. Persistent fever requires adaptation of the
initial antibiotic regimen if the clinical condition dete-
riorates or if a resistant pathogen is isolated. Addition
of an antifungal agent must be considered. Giving the
growing emergence of multidrug-resistant bacteria, the
implementation of antibiotic stewardship programs is
now mandatory.
Author details
1Department of Anesthesiology and Critical Care, Lariboisière Hospital,
Assistance Publique - Hopitaux de Paris, University of Paris 7 Denis Diderot, 2
rue Ambroise-Paré, 75475 Paris, Cedex 10, France
2Medical Intensive Care
Unit, AP-HP, Saint-Louis Hospital, 1 rue Claude Vellefaux, Assistance Publique
- Hopitaux de Paris, University of Paris 7 Denis Diderot, 75010, Paris, France
3Department of Intensive Care and Infectious Diseases, Institut Gustave
Roussy, 39, rue Camille Desmoulins, 94805 Villejuif cedex, France
Authors’ contributions
ML and AM wrote the first draft of the manuscript. BS, EA, and BG revised
the manuscript. All authors read and approved the final version.
Competing interests
The authors declare that they have no competing interests.
Received: 20 May 2011 Accepted: 15 June 2011 Published: 15 June 2011
References
1. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R,
Pizzo PA, Rolston KV, Shenep JL, Young LS: 2002 guidelines for the use of
antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis
2002, 34:730-751.
2. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II,
Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America:
Clinical practice guideline for the use of antimicrobial agents in
neutropenic patients with cancer. In Clin Infect Dis. Volume 52. 2010
update of the Infectious Diseases Society of America; 2011:e56-e59.
3. Pene F, Percheron S, Lemiale V, Viallon V, Claessens YE, Marque S,
Charpentier J, Angus DC, Cariou A, Chiche JD, Mira JP: Temporal changes
in management and outcome of septic shock in patients with
malignancies in the intensive care unit. Crit Care Med 2008, 36:690-696.
4. Thiery G, Azoulay E, Darmon M, Ciroldi M, De Miranda S, Levy V, Fieux F,
Moreau D, Le Gall JR, Schlemmer B: Outcome of cancer patients
considered for intensive care unit admission: a hospital-wide
prospective study. J Clin Oncol 2005, 23:4406-4413.
5. Buchheidt D, Bohme A, Cornely OA, Fatkenheuer G, Fuhr HG, Heussel G,
Junghanss C, Karthaus M, Kellner O, Kern WV, Schiel X, Sezer O, Sudhoff T,
Szelenyi H: Diagnosis and treatment of documented infections in
neutropenic patients–recommendations of the Infectious Diseases
Working Party (AGIHO) of the German Society of Hematology and
Oncology (DGHO). Ann Hematol 2003, 82(Suppl 2):S127-S132.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB:
Nosocomial bloodstream infections in US hospitals: analysis of 24,179
cases from a prospective nationwide surveillance study. Clin Infect Dis
2004, 39:309-317.
7. Zinner SH: Changing epidemiology of infections in patients with
neutropenia and cancer: emphasis on gram-positive and resistant
bacteria. Clin Infect Dis 1999, 29:490-494.
8. Kamana M, Escalante C, Mullen CA, Frisbee-Hume S, Rolston KV: Bacterial
infections in low-risk, febrile neutropenic patients. Cancer 2005,
104:422-426.
9. Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas PA, Federspiel J,
Athan E, Stryjewski ME, Nacinovich F, Marco F, Levine DP, Elliott TS,
Fortes CQ, Tornos P, Gordon DL, Utili R, Delahaye F, Corey GR, Fowler VG Jr:
Emergence of coagulase-negative staphylococci as a cause of native
valve endocarditis. Clin Infect Dis 2008, 46:232-242.
10. Ramphal R: Changes in the etiology of bacteremia in febrile neutropenic
patients and the susceptibilities of the currently isolated pathogens. Clin
Infect Dis 2004, 39(Suppl 1):S25-S31.
11. Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R: Emergence of
Carbapenem resistant Gram negative and vancomycin resistant Gram
positive organisms in bacteremic isolates of febrile neutropenic patients:
a descriptive study. BMC Infect Dis 2008, 8:80.
12. Kanamaru A, Tatsumi Y: Microbiological data for patients with febrile
neutropenia. Clin Infect Dis 2004, 39(Suppl 1):S7-S10.
13. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B,
Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T: Predictors of mortality in
patients with bloodstream infections caused by extended-spectrum-
beta-lactamase-producing Enterobacteriaceae: importance of inadequate
initial antimicrobial treatment. Antimicrob Agents Chemother 2007,
51:1987-1994.
14. Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS:
Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates
from 24 U.S. hospitals. Antimicrob Agents Chemother 2002, 46:3837-3842.
15. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C,
Almela M, Almirante B, Grill F, Colomina J, Gimenez M, Oliver A,
Horcajada JP, Navarro G, Coloma A, Pascual A: Community-onset
bacteremia due to extended-spectrum beta-lactamase-producing
Escherichia coli: risk factors and prognosis. Clin Infect Dis 50:40-48.
16. Cuzon G, Naas T, Nordmann P: KPC carbapenemases: what issue in
clinical microbiology? Pathol Biol (Paris) 58:39-45.
17. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E,
Signorini L, Re A, Carosi G, Rossi G: Recent changes in bacterial
epidemiology and the emergence of fluoroquinolone-resistant
Escherichia coli among patients with haematological malignancies:
results of a prospective study on 823 patients at a single institution. J
Antimicrob Chemother 2008, 61:721-728.
18. European Antimicrobial Resistance surveillance System 2008. [http://
www.rivm.nl/earss/database/:].
19. Mattner F, Biertz F, Ziesing S, Gastmeier P, Chaberny IF: Long-term
persistence of MRSA in re-admitted patients. Infection 2010, 38:363-71.
Legrand et al. Annals of Intensive Care 2011, 1:22
http://www.annalsofintensivecare.com/content/1/1/22
Page 8 of 920. Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP,
Rupp ME, Chambers HF, Karchmer AW, Boucher HW: Initial low-dose
gentamicin for Staphylococcus aureus bacteremia and endocarditis is
nephrotoxic. Clin Infect Dis 2009, 48:713-721.
21. Bayer AS, Murray BE: Initial low-dose aminoglycosides in Staphylococcus
aureus bacteremia good science, urban legend, or just plain toxic? Clin
Infect Dis 2009, 48:722-724.
22. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D,
Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y,
Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S: Cooperative
Antimicrobial Therapy of Septic Shock (CATSS) Database Research
Group. Early combination antibiotic therapy yields improved survival
compared with monotherapy in septic shock: a propensity-matched
analysis. Crit Care Med 2010, 38:1773-85.
23. Picazo JJ: Management of the febrile neutropenic patient: a consensus
conference. Clin Infect Dis 2004, 39(Suppl 1):S1-S6.
24. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L: Efficacy and safety of
cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007,
7:338-348.
25. Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T,
Ho AD, Egerer G: Piperacillin/tazobactam vs ceftazidime in the treatment
of neutropenic fever in patients with acute leukemia or following
autologous peripheral blood stem cell transplantation: a prospective
randomized trial. Bone Marrow Transplant 2006, 37:373-379.
26. Feld R, DePauw B, Berman S, Keating A, Ho W: Meropenem versus
ceftazidime in the treatment of cancer patients with febrile neutropenia:
a randomized, double-blind trial. J Clin Oncol 2000, 18:3690-3698.
27. Han XY, Kamana M, Rolston KV: Viridans streptococci isolated by culture
from blood of cancer patients: clinical and microbiologic analysis of 50
cases. J Clin Microbiol 2006, 44:160-165.
28. Meunier F, Lukan C: The First European Conference on Infections in
Leukaemia - ECIL1: a current perspective. Eur J Cancer 2008, 44:2112-2117.
29. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ:
Efficacy and safety of linezolid compared with vancomycin in a
randomized, double-blind study of febrile neutropenic patients with
cancer. Clin Infect Dis 2006, 42:597-607.
30. Rolston KV, McConnell SA, Brown J, Lamp KC: Daptomycin use in patients
with cancer and neutropenia: data from a retrospective registry. Clin Adv
Hematol Oncol 2010, 8:249-256, 290.
31. Almyroudis NG, Segal BH: Prevention and treatment of invasive fungal
diseases in neutropenic patients. Curr Opin Infect Dis 2009, 22:385-393.
32. Ruping MJ, Vehreschild JJ, Cornely OA: Patients at high risk of invasive
fungal infections: when and how to treat. Drugs 2008, 68:1941-1962.
33. Spanakis EK, Aperis G, Mylonakis E: New agents for the treatment of
fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis
2006, 43:1060-1068.
34. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A,
Bulitta JB, Tsuji BT: Resurgence of colistin: a review of resistance, toxicity,
pharmacodynamics, and dosing. Pharmacotherapy 2010, 30:1279-1291.
35. Lu Q, Girardi C, Zhang M, Bouhemad B, Louchahi K, Petitjean O, Wallet F,
Becquemin MH, Le Naour G, Marquette CH, Rouby JJ: Nebulized and
intravenous colistin in experimental pneumonia caused by Pseudomonas
aeruginosa. Intensive Care Med 36:1147-1155.
36. Raad I, Hanna H, Maki D: Intravascular catheter-related infections:
advances in diagnosis, prevention, and management. Lancet Infect Dis
2007, 7:645-657.
37. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, Raad II,
Rijnders BJ, Sherertz RJ, Warren DK: Clinical practice guidelines for the
diagnosis and management of intravascular catheter-related infection:
2009 Update by the Infectious Diseases Society of America. Clin Infect Dis
2009, 49:1-45.
38. Lortholary O, Lefort A, Tod M, Chomat AM, Darras-Joly C, Cordonnier C:
Pharmacodynamics and pharmacokinetics of antibacterial drugs in the
management of febrile neutropenia. Lancet Infect Dis 2008, 8:612-620.
39. Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC, Craig WA, Billeter M,
Dalovisio JR, Levine DP: Vancomycin therapeutic guidelines: a summary
of consensus recommendations from the infectious diseases Society of
America, the American Society of Health-System Pharmacists, and the
Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49:325-327.
40. Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, Sidi A,
Almog Y: Pharmacokinetic dosing of aminoglycosides: a controlled trial.
Am J Med 2003, 114:194-198.
41. Lamoth F, Buclin T, Pascual A, Calandra T, Marchetti O: Imipenem
underdosing as a cause of persistent neutropenic fever? J Antimicrob
Chemother 2009, 64:665-667.
42. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA:
Pharmacokinetics and pharmacodynamics of meropenem in febrile
neutropenic patients with bacteremia. Ann Pharmacother 2005, 39:32-38.
43. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA: Comparative
pharmacokinetics of the carbapenems: clinical implications. Clin
Pharmacokinet 2000, 39:185-201.
44. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I: Perils of quinolone
exposure in cancer patients: breakthrough bacteremia with multidrug-
resistant organisms. Cancer 116:967-973.
45. Reuter S, Kern WV, Sigge A, Dohner H, Marre R, Kern P, von Baum H:
Impact of fluoroquinolone prophylaxis on reduced infection-related
mortality among patients with neutropenia and hematologic
malignancies. Clin Infect Dis 2005, 40:1087-1093.
46. Carratalà J, Rosón B, Fernández-Sevilla A, Alcaide F, Gudiol F: Bacteremic
pneumonia in neutropenic patients with cancer: causes, empirical
antibiotic therapy, and outcome. Arch Intern Med 1998, 158:868-872.
47. Gruson D, Hilbert G, Portel L, Boiron JM, Bebear CM, Vargas F, Bebear C,
Reiffers J, Gbikpi-Benissan G, Cardinaud JP: Severe respiratory failure
requiring ICU admission in bone marrow transplant recipients. Eur Respir
J 1999, 13:883-887.
48. Regazzoni CJ, Khoury M, Irrazabal C, Myburg C, Galvalisi NR, O’Flaherty M,
Sarquis SG, Poderoso JJ: Neutropenia and the development of the
systemic inflammatory response syndrome. Intensive Care Med 2003,
29:135-138.
49. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A,
Rapoport B, Rolston K, Paesmans M: Bacteraemia in febrile neutropenic
cancer patients. Int J Antimicrob Agents 2007, 30(Suppl 1):S51-S59.
50. Metallidis S, Kollaras P, Giannakakis T, Seitanidis B, Kordosis T, Nikolaidis J,
Hatzitolios A, Nikolaidis P: A prospective, controlled, randomized, non-
blind, comparative study of the efficacy and safety of a once daily high
dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime
plus amikacin in empirical therapy for febrile neutropenic patients. Eur J
Intern Med 2008, 19:619-624.
51. de la Rubia J, Montesinos P, Martino R, Jarque I, Rovira M, Vazquez L,
Lopez J, Batlle M, de la Camara R, Julia A, Lahuerta JJ, Deben G, Diaz J,
Garcia R, Sanz MA: Imipenem/cilastatin with or without glycopeptide as
initial antibiotic therapy for recipients of autologous stem cell
transplantation: results of a Spanish multicenter study. Biol Blood Marrow
Transplant 2009, 15:512-516.
doi:10.1186/2110-5820-1-22
Cite this article as: Legrand et al.: The strategy of antibiotic use in
critically ill neutropenic patients. Annals of Intensive Care 2011 1:22.
Submit your manuscript to a 
journal and beneﬁ  t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ  eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Legrand et al. Annals of Intensive Care 2011, 1:22
http://www.annalsofintensivecare.com/content/1/1/22
Page 9 of 9